Tower Research Capital (TRC)’s Calliditas Therapeutics AB American Depositary Shares CALT Stock Holding History

Tower Research Capital (TRC)’s Portfolio CALT Stock Details CALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-3,357	Closed	-$51K	–	6524
2022 Q3	$51K	Buy	3,357 +3,112	+1,270%	+$54.2K	﹤0.01%	3145
2022 Q2	$4K	Sell	245 -138	-36%	-$2.4K	﹤0.01%	5281
2022 Q1	$7K	Sell	383 -513	-57%	-$10.3K	﹤0.01%	4788
2021 Q4	$22K	Buy	+896	New	+$18K	﹤0.01%	3579
2021 Q2	–	Sell	-76	Closed	-$2K	–	5940
2021 Q1	$2K	Buy	+76	New	+$2.27K	﹤0.01%	5069
2020 Q3	–	Sell	-64	Closed	-$1K	–	5168
2020 Q2	$1K	Buy	+64	New	+$1.27K	﹤0.01%	4658

Other funds holding CALT

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

IIM

Ironwood Investment Management Boston, Massachusetts $240M AUM 45.82% 1-Year Est. Return

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

HSA

HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Tower Research Capital (TRC)'s CALT Position: Q4 2022 in Review

Tower Research Capital (TRC) sold out of Calliditas Therapeutics AB American Depositary Shares (CALT) in Q4 2022, closing a stake of 3,357 shares — an estimated $51K sold.

Tower Research Capital (TRC) first reported a position in CALT in Q2 2020 and held it in 6 quarters. The position peaked at $51K in Q3 2022. 18 funds tracked by Wall St. Rank hold CALT as of Q4 2022.

Tower Research Capital (TRC) reported no remaining Calliditas Therapeutics AB American Depositary Shares position as of Q4 2022 after selling out during the quarter.
Tower Research Capital (TRC) sold 3,357 Calliditas Therapeutics AB American Depositary Shares shares in Q4 2022, an estimated $51K.
Tower Research Capital (TRC) first reported a position in Calliditas Therapeutics AB American Depositary Shares in Q2 2020 and held it in 6 quarters.
Tower Research Capital (TRC)'s Calliditas Therapeutics AB American Depositary Shares position peaked at $51K in Q3 2022.
18 funds tracked by Wall St. Rank held Calliditas Therapeutics AB American Depositary Shares as of Q4 2022.

Based on Tower Research Capital (TRC)'s 13F filing for Q4 2022, filed 10 Feb 2023.